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Supplements 
Covariates 
Covariates included patient characteristics (age, gender, body mass index [BMI]), lifestyle 
factors (smoking status and alcohol consumption), comorbidities and drug treatment. Only 
GP records occurring within the 5-year period before initial diagnosis of gout were used to 
evaluate comorbidities and drug treatment. Comorbidities were grouped into 17 diagnostic 
categories (myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic 
ulcer disease, mild liver disease, moderate or severe liver disease, diabetes mellitus [DM], 
DM with chronic complications, renal diseases, any malignancy [including leukaemia and 
lymphoma], metastatic solid tumour and human immunodeficiency virus [HIV] infection) for 
calculation of the Charlson comorbidity index[52, 53] and other comorbidities (alcohol 
abuse, anaemia, cardiac arrhythmias, depression, drug abuse, hip fracture, hypertension, 
hypothyroidism, multiple sclerosis, neurological diseases, psoriasis, psychosis, urolithiasis 
and valvular heart disease). The definitions of these conditions were also based on physician 
diagnoses recorded as READ codes. Medications evaluated include aspirin, anticoagulants, 
anticonvulsants, lipid lowering agents (statin, fibrate and other), antihypertensives 
(angiotensin converting enzyme inhibitor/angiotensin-receptor antagonist, beta blockers, 
calcium channel blockers, diuretics and other), nitrates, other cardiovascular medications,  
insulin, other hypoglycaemic agents, anti-inflammatory agents (non-steroid anti-
inflammatory drugs [NSAIDs], colchicine, corticosteroids), bisphosphonate and vitamin D.  
Propensity score adjustment analysis 
Similar results were obtained to our main analysis when we used propensity score adjustment 
for all included patients in both the one-year and three-year landmark analysis. In the one-
year landmark analysis, allopurinol was associated with an unadjusted hazard ratio (95% 
confidence interval) of 1.49 (1.32─1.67) and a propensity score adjusted hazard ratio (95% 
confidence interval of 1.02 (0.95─1.09) for all-cause mortality. In the three-year analysis, the 
unadjusted and propensity score-adjusted hazard ratios (95% confidence interval) were 1.35 
(1.26─1.44) and 1.05 (0.93─1.20), respectively. 
  
Supplementary table 1. Performance of CPRD recorded death 
 Death registration 
Total PPV NPV 
GPRD recorded Not recorded 
Recorded 195,047 14,107 209,154 93.3%  
Not recorded 2,092 3,311,355 3,313,447  99.9% 
Total 197,139 3,325,462 3,522,601   
Sensitivity 98.94% 99.6%    
Footnote: PPV, positive predictive value; NPV, negative predictive value. 
 
  
Supplementary Table 2. Characteristics of cohort at cohort entry (initial diagnosis of gout). 
Values are numbers (percentage) unless stated otherwise. 
  Entire 
cohort 
(n=23,332) 
 One-year Landmark cohort  Three-year landmark cohort 
   Included 
patients 
(n=21,947) 
Excluded 
patients 
(n = 1,385) 
P value  Included 
patients 
(n=19,549) 
Excluded 
patients 
(n=3,783) 
P 
value 
Age (years)           
Median (interquartile 
range) 
 62 (50─73)  62 (49─73) 73 (60─82) <0.001  61 (49─71) 72 (58─81) <0.001 
Gender           
Men   17,197 
(73.71) 
 16,276 
(74.16) 
921 (66.50) <0.001  14,628 
(74.83) 
2,569 
(67.91) 
<0.001 
Women  6,135 
(26.29) 
 5,671 (25.84) 464 (33.50)   4,921 (25.17) 1,214 
(32.09) 
 
BMI (kg/m2)           
<18.5  162 (0.69)  146 (0.67) 16 (1.16) <0.001  123 (0.63) 39 (1.03) <0.001 
18.5 – 24.9  4,975 
(21.32) 
 4,678 (21.31) 297 (21.44)   4,142 (21.19) 833 (22.02)  
25.0 – 29.9  8,910 
(38.19) 
 8,536 (38.89) 374 (27.00)   7,846 (40.14) 1,064 
(28.13) 
 
≥30  6,119 
(26.23) 
 5,889 (26.83) 230 (16.61)   5,466 (27.96) 653 (17.26)  
Unknown   3,166 
(13.57) 
 2,698 (12.29) 468 (33.79)   1,972 (10.09) 1,194 
(31.56) 
 
Smoking           
Non-smoker  2,688 
(11.52) 
 2,523 (11.50) 165 (11.91) 0.80  2,307 (11.80) 381 (10.07) 0.03 
Current smoker  1,910 (8.19)  1,804 (8.22) 106 (7.65)   1,588 (8.12) 322 (8.51)  
Ex-smoker  13,889 
(59.53) 
 13,059 
(59.50) 
830 (59.93)   11,543 
(59.05) 
2,346 
(62.01) 
 
Unknown  4,845 
(20.77) 
 4,561 (20.78) 284 (20.51)   4,111 (21.03) 734 (19.40)  
Alcohol consumption 
(units/week) 
          
Never/ Ex-drinker  2,525 
(10.82) 
 2,299 (10.48) 226 (16.32) 0.07  1,992 (10.19) 533 (14.09) 0.35 
Current 1-9   8,957 
(38.39) 
 8,421 (38.37) 536 (38.70)   7,461 (38.17) 1,496 
(39.55) 
 
Current ≥10  5,496 
(23.56) 
 5,281 (24.06) 215 (15.52)   4,799 (24.55) 697 (18.42)  
Unknown  6,354 
(27.23) 
 5,946 (27.09) 408 (29.46)   5,297 (27.10) 1,057 
(27.94) 
 
Charlson 
comorbidity index 
          
0 
 16,211 
(69.48) 
 15,575 
(70.97) 
636 (45.92) <0.001  14,365 
(73.48) 
1,846 
(48.80) 
<0.001 
1-2 
 5,916 
(25.36) 
 5,384 (24.53) 532 (38.41)   4,476 (22.90) 1,440 
(38.07) 
 
3-4  1,141 (4.89)  947 (4.31) 194 (14.01)   687 (3.51) 454 (12.00)  
≥4  64 (0.27)  41 (0.19) 23 (1.66)   21 (0.11) 43 (1.14)  
Medications           
Aspirin 
 4,188 
(17.95) 
 3,750 (17.09) 438 (31.62) <0.001  3,047 (15.59) 1,141 
(30.16) 
<0.001 
Statin  105 (4.52)  986 (4.49) 69 (4.98) 0.40)  883 (4.52) 172 (4.55) 0.94 
Diuretics 
 8,878 
(38.05) 
 8,023 (36.56) 855 (61.73) <0.001)  6,687 (34.21) 2,191 
(57.92) 
<0.001 
Insulin  122 (0.52)  103 (0.47) 19 (1.37) <0.001)  84 (0.43) 38 (1.00) <0.001 
NSAID 
 17,024 
(72.96) 
 16,045 
(73.11) 
979 (70.69) 0.50  14,324 
(73.27) 
2,700 
(71.37) 
0.02 
  
Supplementary Table 3. Comparison of patients exposed to or unexposed to allopurinol 
within three year from initial diagnosis of gout before and after matching. Values are numbers 
(percentage) unless described otherwise. 
  Exposure groups before matching  Exposure groups after matching 
  Allopurinol 
users 
(n=3,540) 
Allopurinol 
nonusers 
(n = 16,009) 
P 
value 
 Allopurinol 
users 
(n = 3,519) 
Allopurinol 
nonusers 
(n = 3,519) 
P 
value 
Age (years)         
Median (interquartile 
range) 
 64 (52─73) 60 (48─71) <0.001  64 (52─73) 63 (51─73) 0.69 
Gender         
Men   2,530 (71.90) 12,085 (75.49) <0.001  2,530 (71.90) 2,542 (72.24) 0.75 
Women  989 (28.10) 3,924 (24.51)   989 (28.10) 977 (27.76)  
BMI (kg/m2)         
<18.5  14 (0.40) 109 (0.68) 0.009  14 (0.40) 16 (0.5) 0.93 
18.5 – 24.9  633 (17.99) 3,508 (21.91)   633 (17.99) 642 (18.24)  
25.0 – 29.9  1,357 (38.56) 6,482 (40.49)   1,357 (38.56) 1,351 (38.39)  
≥30  1,205 (34.24) 4,248 (26.54)   1,205 (34.24) 1,202 (34.16)  
Unknown   310 (8.81) 1,662 (10.38)   310 (8.81) 308 (8.78)  
Smoking         
Non-smoker  427 (12.13) 1,877 (11.72) 0.006  427 (12.13) 426 (12.11) 0.93 
Current smoker  273 (7.716) 1,312 (8.21)   273 (7.716) 290 (8.24)  
Ex-smoker  2,136 (60.70) 9,392 (58.62)   2,136 (60.70) 2,117 (60.16)  
Unknown  683 (19.41) 3,426 (21.40)   683 (19.41) 686 (19.49)  
Alcohol consumption 
(units/week) 
        
Never/ Ex-drinker  419 (11.91) 1,567 (9.79) 0.004  419 (11.91) 425 (12.08) 0.79 
Current 1-9   1,391 (39.53) 6,058 (37.84)   1,391 (39.53) 1,369 (38.90)  
Current ≥10  820 (23.30) 3,979 (24.85)   820 (23.30) 846 (24.04)  
Unknown  889 (25.26) 4,405 (27.52)   889 (25.26) 879 (24.98)  
Charlson comorbidity 
index 
        
0  2,330 (66.82) 12,035 (75.18) <0.001  2,329 (66.18) 2,341 (66.52) 0.75 
1-2  1,017 (28.73) 3,459 (21.61)   1,008 (28.64) 999 (28.39)  
3-4  187 (5.28) 500 (3.12)   176 (5.00) 174 (4.49)  
≥4  6 (0.17) 15 (0.09)   6 (0.17) 5 (0.14)  
Medications         
Aspirin  799 (22.57) 2,248 (14.04) <0.001  785 (22.31) 796 (22.62) 0.75 
Statin  263 (7.43) 620 (3.87) <0.001  255 (7.25) 248 (7.05) 0.75 
Diuretics  1,778 (50.23) 4,909 (30.66) <0.001  1,757 (49.93) 1,778 (50.53) 0.62 
Insulin  18 (0.51) 66 (0.41) 0.43  18 (0.51) 14 (0.40) 0.48 
NSAID  2,560 (72.32) 11,764 (73.48) 0.16  2,544 (72.29) 2,549 (72.44) 0.89 
 
  
Figures 
Figure 1.  Diagram of one-year and three-year landmark analysis (a) decomposition of study 
population. (b) details of timeline. 
Figure 2. Kaplan-Meier survival plot for all-cause mortality in (a) one-year and (b) three-year 
landmark analysis. Blue line represents allopurinol users and green line represent nonusers.  
 
 
